The reason for deleting C-term lysine during antibody engineering is to improve the antibody product profile. The C-terminal lysine variation is commonly observed in biopharmaceutical monoclonal antibodies. Monoclonal antibodies display numerous structural attributes, some of them may impact their safety and/or efficacy profiles. C-terminal lysine clipping is a common phenomenon occurring during the bioproduction of monoclonal antibodies and leads to variable amounts of final process-related charge variants. This clipping of the C-terminal lysine may increase antibody product heterogeneity which is to be avoided.
You may want to refer to the references attached below.
YINGJI JIN , it is generally accepted that C-terminal lysine do not significantly affect antibody function. Please refer to the article attached below.